For years, “print a crown while the patient waits” has been more aspiration than clinical routine. Milling has dominated same-day restorative dentistry, and resin-based 3D printing has largely been confined to models, surgical guides, and temporaries. That balance appears to be shifting in light of the latest news in dental 3D printing. Across the first half of 2026, a cluster of regulatory clearances, material launches, and academic results suggests that permanent, chairside-printed restorations are moving from novelty to a real clinical option. Why is this such a big deal? The current permanent crown workflow involves at least two office visits and a minimum of two weeks of waiting time for the crown to be ready for placement. During the weeks between visits, patients often have to wear a clunky, essentially nonfunctional temporary crown. With chairside permanent crown availability, patients can potentially receive same-day treatment, avoiding additional trips to the dentist and the inconveniences of a temporary crown. So it is a huge deal. However, after some investigation, there appear to be real caveats that any dentist or patient should understand before assuming printed crowns can simply replace milled or sintered ones.

The Headline Development: SprintRay’s FDA Clearance for Porcelain Crowns

The most consequential news is SprintRay’s FDA clearance to 3D print porcelain crowns. The company’s CEO, Amir Mansouri, has framed this as roughly 10 times the addressable market of its existing nightguard business, since SprintRay estimates that around 40 million crowns are produced annually in the United States, almost all of them currently routed through outside dental laboratories with a multi-week turnaround. SprintRay’s pitch is that its printers can now produce a crown chairside in 10 to 20minutes, collapsing weeks of lab logistics into a single appointment.

What makes this more interesting is the pricing strategy attached to it. SprintRay is evaluating subscription models to soften the roughly $15,000 upfronthardware cost, an approach explicitly aimed at making the technology accessible to general practices serving middle- and lower-income communities rather than only early-adopter specialty clinics. That’s a meaningful gesture when a company designs financing around volume practices instead of premium cosmetic clinics; it’s betting the technology is ready for the mainstream, not just the showcase.

SprintRay has also been expanding the surrounding ecosystem. Its Midas Digital Press platform uses a capsule-based “Digital Press Stereolithography” approach — resin cartridges that resemble single-use coffee pods — to print crowns in under ten minutes, and the company has previewed multi-unit production capabilities at the 2026 Chicago Midwinter Meeting, with enlarged build capsules intended to let practices fabricate several crowns, inlays, onlays, and veneers in one run rather than one unit at a time. A new “HT” (High Translucency) version of its Ceramic Crown resin specifically targets the chalky, flat appearance that has been a recurring criticism of earlier printed-resin restorations.

Why “Ceramic” Printed Crowns Aren’t Actually Ceramic Crowns

While there are several “permanent crown ceramic” resins out there, here are some details that might get lost in the enthusiasm: The materials industry leaders like SprintRay, Formlabs, Keystone Industries (RODIN), and Ceradirect use for printed crowns are not zirconia or lithium disilicate. They’re resin-matrix composites — biocompatible polymer bases loaded with 50 percent or more ceramic filler, typically silanized dental glass or barium aluminum silicate particles bonded into the resin and cured instantly under 405nm light. This is fundamentally different chemistry from pure ceramics, which rely on a glass matrix with crystalline phases like lithium disilicate or zirconia, an apolycrystalline metal oxide with no glass phase at all — sometimes nicknamed “ceramic steel.”

The practical consequence is strength. These reinforced-resin crowns test at roughly 112to 150 MPa of flexural strength. Lithium disilicate ceramics run 400 to 500 MPa. Zirconia exceeds 1,000 MPa, sometimes reaching 1,200. For context, normal human chewing generates roughly 100 to 150 MPa of force on the back molars, meaning printed resin crowns operate close to the edge of everyday biting forces rather than with the wide safety margin zirconia provides. Clinical forums and dental community feedback reflect this: dentists who’ve tried stretching the material beyond single units — attempting multi-unit bridges, for instance — report high failure and breakage rates, and the material demands a strict minimum wall thickness of 1.0 to 1.5 mm, meaning conservative tooth preparations with thinner margins carry a real fracture risk.

None of this makes the technology useless, but it does make it use-case-specific. The speed and cost advantage is dramatic: a printed resin crown can go from scan to seated restoration in 15 to 45 minutes for a few dollars in material cost, versus a 6-hour-plus mill-and-sinter cycle for zirconia or roughly 45 minutes of milling plus crystallization firing for lithium disilicate. That makes printed resin crowns well suited to single units with moderate bite forces, same-day veneers, and immediate temporaries, while zirconia remains the better choice for heavy grinders, molars under high occlusal load, and bridges, and lithium disilicate still holds the edge for anterior esthetics where light transmission matters most.

Ceramics Are Catching Up on Speed, Too

The clearance race isn’t confined to resin. Researchers at UT Dallas published work in Ceramics International demonstrating same-day chairside 3D-printed zirconia crowns, with debinding — the process of burning out organic binders before sintering — completed in under 30 minutes, rather than the 20-to-100-hour cycles typically required for printed ceramics. If that approach scales beyond the lab, it would narrow the speed gap that has kept true zirconia restorations out of single-visit dentistry, potentially combining zirconia’s mechanical strength with a turnaround time closer to that of resin.

Material jetting is advancing on the prosthetics side as well. 3D Systems secured full EUMDR certification for its NextDent Jetted Dentures workflow, clearing the way for a European launch in summer 2026, and reflecting a broader shift from milling toward additive manufacturing for full-arch removable prosthetics. Meanwhile, Axtra3D and Keystone Industries co-developed KeyModel Ultra Ivory, a non-chipping dental model resin validated specifically for Axtra3D’s Lumia X1 platform — part of a wider industry pattern in which resin and hardware are increasingly co-validated as matched pairs rather than sold as interchangeable, open components, which vendors argue improves clinical predictability but also tends to lock practices into single-vendor ecosystems.

So, Is It Real?

Chairside 3D printing of permanent restorations is real in the sense that FDA-cleared materials and hardware now exist, practices are adopting them, and the economics are increasingly built for general dentistry rather than boutique clinics. It is not yet a wholesale replacement for milled ceramics or sintered zirconia. Clinicians on the front lines remain measured in their enthusiasm. As Nabeel Cajee, DDS, of Advanced Dentistry of Newport Beach, puts it:

“I’m still hesitant to use printed resins for definitive restorations. Zirconia and traditional ceramics remain the gold standard for long-term reliability and aesthetic demand, and I’m not fully convinced the materials are quite there yet. That said, even if the physics never fully match zirconia or glass ceramics, the sheer speed and convenience of chairside fabrication may shift both dentist and patient preferences regardless — patients love same-day results, and that’s a powerful force. This is definitely technology to watch as it matures.”

The honest summary is that dentistry now has a genuine third option alongside milling and lab-based ceramics — fast, cheap, and adequate for the right indication, but not interchangeable with stronger, slower materials for cases that demand them. The technology to watch through the rest of 2026 is whether reinforced resins close the strength gap, whether zirconia closes the speed gap, or whether both simply settle into complementary roles based on where in the mouth — and how fast — a restoration is actually needed.

References:

https://www.voxelmatters.com/sprintray-gets-fda-clearance-to-3d-print-porcelain-dental-crowns

Single-step thermal debinding for ceramics vat photopolymerization in less than 30 minutes

https://www.3dsystems.com/press-releases/3d-systems-secures-class-iia-eu-mdr-certification-nextdentr-jetted-denture-solution

https://3dprintingindustry.com/news/axtra3d-launches-keymodel-ultra-ivory-for-lumia-x1-in-dental-materials-partnership-with-keystone-251592/

The post  Is Chairside 3D-Printed Crown Finally a Reality? appeared first on 3DHeals.

The medical field is undergoing a revolutionary transformation, driven by two cutting-edge technologies: Artificial Intelligence (AI) and 3D printing. When these forces collide, they unleash unparalleled potential for innovation, personalization, and improved patient outcomes. From custom prosthetics to intricate anatomical models for surgical planning, the synergy between AI and 3D printing is reshaping healthcare as we know it. Let’s dive into some of the latest advancements, drawing insights from pioneering researchers and practitioners at the forefront of this exciting intersection.

Personalized Prosthetics for a Better Quality of Life

Creating personalized prosthetics is one of the most compelling applications of AI and 3D printing in healthcare. Merel van der Stelt, a PhD student at 3D Lab Radboudumc, is dedicated to developing prostheses for low- and middle-income countries, utilizing AI for optimized socket shape design (LinkedIn activity). By leveraging AI algorithms, researchers can analyze individual patient data, such as limb shape and movement patterns, to create prosthetics that fit perfectly and function seamlessly. This level of customization enhances comfort, mobility, and overall quality of life for those in need, especially in regions with limited resources.

Moreover, Johann Reinhard, a Research Scientist at Fraunhofer IGD, is pushing the boundaries of 3D printing for eye implants. Using AI to design prints from optical coherence tomography (OCT) images, researchers can create bespoke prosthetic eyes that closely match the patient’s anatomy (New Scientist article). Imagine a future where individuals with eye injuries or congenital disabilities can receive custom-made implants that restore both function and aesthetics. This level of precision and personalization is made possible by AI, which can analyze complex medical images and generate intricate 3D designs.

Enhancing Surgical Planning and Precision

Surgical planning is another area where the combination of AI and 3D printing is making significant strides. Kaiyan Qiu, an assistant professor at Washington State University, uses AI to determine optimal 3D printing parameters for creating surgical planning organ models (WSU press release). Surgeons can generate highly accurate 3D models of patient-specific organs by feeding medical imaging data into AI algorithms. These models allow for detailed pre-operative planning, enabling surgeons to visualize complex anatomical structures and practice procedures before stepping into the operating room. This reduces surgical time and risk and improves patient outcomes by ensuring greater precision and predictability.

Furthermore, Gade Jong, another Assistant Professor, focuses on AI and 3D technologies for anatomical segmentation (Nature article). Precise segmentation of organs and tissues from medical images is crucial for creating accurate 3D models. AI algorithms can automate and refine this process, allowing quicker and more reliable generation of models used in surgical planning. By automating these complex processes, AI enables healthcare professionals to be more efficient and reduce the risk of human error.

Innovations in Bioprinting and Tissue Engineering

Bioprinting, the process of 3D printing living tissues and organs, is a realm where AI is proving invaluable. Ben Kiratitanaporn, a recent PhD graduate, is utilizing AI for 3D cell scaffolds. Cell scaffolds provide the structural support for cells to grow and form functional tissues. AI can optimize the design of these scaffolds, ensuring the proper porosity, mechanical properties, and biocompatibility. Similarly, Guo-Dong Goh, a Research Fellow, focuses on AI for 3D printing tissue-like anatomical models and anomaly detection (ScienceDirect article). AI algorithms can analyze the quality of printed tissues, detecting defects or inconsistencies that might compromise their function.

Associate Professors like Stefanie Mueller at MIT explore human-computer interaction technologies fabricated using 3D printing and AI (MIT news), while Washburn Lab at Carnegie Mellon develops AI for choosing design parameters in the bioprinting of hydrogels (ACS Biomaterials article). Additionally, Demaria at Centro Piaggio, University of Pisa, uses AI to select printing parameters for bioprinting (IJB article). These collective efforts are pushing the boundaries of what’s possible, making the creation of functional tissues and organs closer to reality than ever before.

Drug Delivery and Microneedle Technology

The intersection of AI and 3D printing also opens up exciting possibilities in drug delivery. Moe Elbadawi, a Lecturer, investigates AI, 3D printing, and drug delivery, building upon the work of Alvaro Goyanes at FABRX (ScienceDirect article). By 3D printing personalized drug formulations and delivery devices, we can ensure that patients receive the proper medication in the correct dosage, tailored to their unique needs. This precision approach can improve treatment efficacy and minimize side effects.

Furthermore, Stasoglu at Koç University is leveraging AI to tune 3D printing parameters for microneedle design (MDPI article). Microneedles offer a painless and efficient way to deliver drugs through the skin. AI can optimize the design and fabrication of these tiny needles, enhancing their effectiveness and patient comfort.

Advancements in Wearable Technology and Physiological Monitoring

Wearable technology is another area benefiting from the AI-3D printing synergy. Wei Gao, a professor at Caltech, developed 3D-printed electronic wearable skin that uses AI for physiological monitoring (Science article). These innovative devices can continuously track vital signs and other health indicators, providing valuable data for personalized medicine and early disease detection. Imagine a world where wearable sensors seamlessly integrate with the body, continuously monitoring health and sending alerts when needed.

Defect Detection and Quality Control

Amedeo Bonatti (ORCID) uses AI, particularly expert systems, for defect detection in electron beam melted implants (Liebertpub article). Ensuring the quality and structural integrity of 3D-printed medical devices is critical for patient safety. AI algorithms can analyze 3D-printed objects in detail, identifying any defects or anomalies that might compromise their function. This level of quality control ensures that medical devices meet the highest standards of safety and efficacy.

Devin Roach at Oregon State University also applies AI to 3D printing for biomedical applications. His co-authored article titled “Invertible Neural Networks for Real-Time Control of Extrusion Additive Manufacturing” explores the application of machine learning, specifically invertible neural networks (INNs), to enhance the precision and adaptability of direct ink write (DIW) 3D printing processes. This research is particularly relevant to healthcare due to its potential to improve the fabrication of customized medical devices and implants.(ScienceDirect) Integrating INNs allows for real-time monitoring and optimization of the printing process, ensuring that these medical products meet stringent quality and performance standards. By enabling adaptive control during fabrication, this approach can lead to more reliable and efficient production of complex biomedical structures, ultimately enhancing patient outcomes.

The Future Outlook

The advancements discussed above represent the exciting possibilities when AI and 3D printing intersect in healthcare. As these technologies evolve, we can expect even more groundbreaking innovations. The ability to create personalized medical devices, plan complex surgeries precisely, bioprint functional tissues, and develop advanced drug delivery systems will revolutionize patient care. The integration of AI enhances this process through analysis, automation, and control to ensure that we receive the highest level of patient care. This exciting field has tremendous potential to transform the healthcare landscape and improve lives worldwide.

To learn more about these exciting developments, don’t miss our upcoming virtual event focusing on this very topic.

Keywords: AI in healthcare, 3D printing, personalized medicine, bioprinting, surgical planning, drug delivery, wearable technology.

Related links:

• Artificial Intelligence and Machine Learning in 3D Printing, AR/VR Explores how AI and machine learning are optimizing design, predictive maintenance, quality control, and patient-specific modeling for 3D-printed medical devices and implants. The article also discusses how AI/ML can reduce costs and improve patient outcomes.
• Artificial Intelligence in Healthcare 3D Printing (Webinar) Recap and resources from a theme-based webinar featuring industry and academic leaders discussing the latest AI-driven advancements in healthcare 3D printing.
• When Artificial Intelligence Meets 3D Printing An in-depth article explaining the basics of AI and machine learning, their relevance to 3D printing, and the challenges of integrating AI into real-time 3D printing monitoring and quality control.

Additional 3DHEALS Resources:

1. https://3dheals.com/product/artificial-intelligence-and-machine-learning-in-3d-printing-ar-vr/
2. https://3dheals.com/machine-learning-in-3d-printing-and-bioprinting-a-collection-of-recent-publications/
3. https://3dheals.com/artificial-intelligence-for-segmentation/
4. https://3dheals.com/product/artificial-intelligence-in-healthcare-3d-printing/
5. https://3dheals.com/courses/artificial-intelligence-in-healthcare-3d-printing/
6. https://3dheals.com/artificial-intelligence-updates-for-3d-printing-and-bioprinting/
7. https://3dheals.com/when-artificial-intelligence-meets-3d-printing/
8. https://3dheals.com/tag/machine-learning/
9. https://3dheals.com/artificial-intelligence-and-3d-printing/
10. https://www.youtube.com/c/3DHEALSINNOVATION
11. https://3dheals.com/interview-with-kerim-genc-the-power-of-artificial-intelligence-and-3d-printing/

The post AI in Healthcare 3D Printing: The Future is Now appeared first on 3DHeals.

Mohit P. Chhaya, PhD, is a biomedical engineer with a career marked by pioneering contributions to biofabrication and tissue engineering. A Queensland University of Technology alum, Dr. Chhaya has authored numerous Q1 top-tier journal publications and developed cutting-edge technologies licensed by leading 3D BioPrinter manufacturers. As the co-founder and CEO of BellaSeno, he successfully raised EUR 17 million, steering the company towards ISO 13485 certification and steering its flagship product, Senella, through clinical translation. His tenure at BellaSeno also involved transforming it into a multi-product company and achieving market authorization for innovative, best-in-class regenerative scaffolds.
Before founding BellaSeno, Dr. Chhaya co-founded Biofabrication Design Solutions, focusing on additive manufacturing for multi-material constructs. His professional journey includes roles in regulatory affairs, postdoctoral research, and financial analysis, demonstrating a broad skill set beyond bioengineering. Dr. Chhaya’s innovations have garnered international recognition, earning him prestigious awards such as the MIT Top 20 Innovators Under 35 and the German Innovation Award 2021. An active ASTM Committee on Additive Manufacturing member and a respected speaker at international conferences, Dr. Chhaya is deeply involved in advancing biofabrication standards and education. His remarkable IP portfolio includes numerous patents and designs across various jurisdictions, underscoring his contribution to medical technology innovation. Dr. Chhaya will be speaking at the upcoming 3D printing for breast implants event. Also, check out the link below for a recent podcast I did with Dr. Chhaya.

When was the first encounter you had with 3D printing? What was that experience like? What were you thinking at that moment?

My first encounter with 3D printing occurred during my Honours year in biomedical engineering. I was working on a project involving preparing histological sections of scaffolds implanted in sheep to regenerate bone tissue. Within the same lab, a team was assembling a custom-built bioprinter. Witnessing the creation of complex structures with such precision felt like stepping into the future. At that moment, I realized the potential for 3D printing to revolutionize medical treatments.

Noticing that most G-code for fabricating the scaffolds was written by hand, which was highly inefficient, I leveraged my programming skills from previous freelance work for bioinformaticians. I offered to design custom slicer scripts specifically for fabricating scaffolds for tissue engineering. Professor Dietmar Hutmacher, who led the project, accepted my offer and introduced me to his postdoc. This experience was the catalyst for my journey into 3D printing.

What inspired you to start your journey?

The inspiration to start BellaSeno was deeply personal. Like many, I have a family history of breast cancer; my grandmother was diagnosed in the 90s and underwent a lumpectomy, but reconstruction options were limited. The prospect of full biological regeneration through 3D printing was no longer science fiction, and I was compelled to pursue this technology to create better solutions for patients like my grandmother.

Who inspired you the most along this journey in 3D printing?

Several individuals have been instrumental in my journey. My grandmother, whose experience with breast cancer sparked my passion; my PhD supervisors, who guided my academic and professional growth; and the investors in BellaSeno, whose belief in our vision has been unwavering. Most importantly, the patients whose lives have been transformed by our products continue to inspire and motivate me daily.

What motivates you the most for your work?

The most significant motivation for my work is the tangible positive impact on patients’ lives. At BellaSeno, we focus on treating patients who have experienced complications with silicone implants and seek a better alternative. These patients often have limited options and fall through the cracks in the medical system. Seeing their physical and emotional well-being improve after receiving our scaffolds is incredibly motivating.

What is/are the biggest obstacle(s) in your line of work? If you have conquered them, what were your solutions?

One of the biggest obstacles has been the regulatory challenges in getting new medical devices approved. Navigating these regulations requires a deep understanding of both the technology and the legal landscape.

We realized that the breast implant industry, including regulators like the FDA, needed to be educated on new technologies like scaffolds. The FDA offers defined interaction pathways, which we utilized to gain clarity. In the EU, we leveraged the Custom-Made device pathway to market our scaffolds for lower-risk applications. Demonstrating the safety and efficacy of our technology in real-world scenarios has paved the way for broader approval in breast surgeries.

What do you think is (are) the biggest challenge(s) in 3D Printing/bio-printing? What do you think the potential solution(s) is (are)?

The biggest challenge in 3D printing and bio-printing is scalability. While creating prototypes and small batches is feasible, scaling up production for widespread use at a reasonable cost is complex.

To address this, we initiated a 3D printing innovation program, drawing inspiration from traditional plastic processing industries. We developed a comprehensive in-house software and hardware stack, including scaffold design, slicing, 3D printers, and post-processing equipment. This infrastructure allows us to scale production to over one million units annually, with costs comparable to silicone implant manufacturing.

Beyond this challenge, the 3D printing industry needs to evolve from being just a cool piece of technology to a routinely used manufacturing method. Innovation must come from the product side beyond simple customization. This means developing innovative designs and performance features that can only be realized with 3D printing, thus unlocking the full potential of the technology.

If you are granted three wishes by a higher being, what would they be?

1. Universal access to food.
2. Aging gracefully.
3. Discontent – not quite satisfied with what I have but driven to do better.

What advice would you give to a smart driven college student in the “real world”? What bad advice should they ignore?

My advice is to be tenacious. The real world is full of challenges without ready-made solutions, but dedication and continuous learning will help you overcome them.

Ignore the bad advice that a great idea originating in a university lab is 90% of the work toward a successful startup. Execution and perseverance are keys to turning an idea into a thriving business.

What’s your favorite book you read this year and why? Alternatively, what’s your favorite book of all times you read and why?

My favorite book this year is “Alexander the Great and the Logistics of the Macedonian Army” by DW Engels. While many historical books focus on Alexander’s biography and strategies, this one highlights the critical role of logistics in his strategic victories. It offers interesting parallels with the business world, where strategy is often emphasized, but the nuts and bolts of execution are equally important.

Relevant Links:

Interview with Esther Valliant: Bioglass for 3D Printing

Interview with Dr. Bryan Scheer: From Bedside To SiNAPTIC Technologies

Past 3DHEALS Influencer Interviews

3DHEALS Lattice Podcast

Interested in sponsoring our podcast? Contact: info@3dheals.com

The post Interview Dr. Mohit Chhaya: BellaSeno appeared first on 3DHeals.

Dr. Mohammad Albanna, PhD is the founder and CEO of Humabiologics, one of the only regenerative medicine companies focused on developing and commercializing human-derived biomaterials to researchers around the world for regenerative medicine applications. He holds a PhD in Biomedical Engineering, 2 master’s degrees in Materials Sciences and Electrical & Computer Engineering and completed a postdoctoral fellowship at Wake Forest Institute of Regenerative Medicine, where he served as the lead of the skin bioprinting group and is currently an adjunct assistant professor of Surgery at Atrium Health Wake Forest Baptist. Dr. Albanna authored several peer-reviewed papers, book chapters and is the inventor of several issued and patent-pending applications. Dr. Albanna has 15 years of industry experience, during which he has held several senior and executive leadership positions across several industries including medical devices, blood banking, and tissue banking. His work in regenerative medicine was recognized through several prestigious awards including 2013 Thomas Edison Gold Award in Innovation, 2018 Arizona Innovator of the year finalist, and 2021 Arizona Leader in Innovation Award. Dr. Albanna will be a speaker at our upcoming 3DHEALS Biomaterials 2024 virtual event.

When was the first encounter you had with 3D printing? What was that experience like? What were you thinking at that moment?

Mohammad: My introduction to 3D printing occurred unexpectedly during my academic journey. Initially trained as a medical device engineer, I later pursued a master’s degree in electrical and computer engineering. I thought my electrical engineering background might not find direct application in my subsequent focus on tissue engineering during my Ph.D. in Biomedical Engineering.

In 2011, the Wake Forest Institute of Regenerative Medicine (WFIRM) recruited me to lead their skin bioprinting research group. It was a pivotal moment that brought my diverse skill set into play. With no commercially available bioprinter on the market at the time, I found myself tasked with the challenge of constructing a skin bioprinter and a wound scanning system from scratch.

The idea of printing living human tissue directly onto patients, particularly to aid those with extensive third-degree burns like wounded warriors, was initially difficult to grasp. Just a year earlier, I had been grappling with printing my thick Ph.D. dissertation, never imagining that I would soon be printing living human tissue directly onto burn wounds. What struck me most was the transformative potential of this technology to revolutionize healthcare and improve the lives of those in need. Leading a team with diverse backgrounds towards the common goal of bioprinting human skin was not only a professional challenge but also a deeply inspiring and humbling opportunity.

What inspired you to start your journey?

Mohammad: As the team’s goal was to transition our bioprinting endeavors from preclinical models to patients, we encountered a significant hurdle: the lack of suitable bioinks in the market that were both human-sourced and capable of facilitating healthy tissue remodeling after severe burn injuries. I immediately recognized the pressing need for human-derived biomaterials to support our research and the broader regenerative medicine field. I started a company with a goal to provide human biomaterials and bioink. I quickly realized that launching a successful business requires more than just scientific expertise. It requires a comprehensive understanding of business operations, supply chain management, and market dynamics. This realization led me to pivot from academia to industry, embarking on a decade-long journey of continuous learning and professional growth. Throughout this journey, I assumed various roles, lived in different states, and worked with great mentors and leaders. Each experience contributed to my growth and provided me with the skills and confidence necessary to pursue my entrepreneurial ambition. The pivotal point was during my tenure in tissue banking, where I worked closely with donated human tissues on a daily basis. This immersive experience not only deepened my appreciation for the significant impact of tissue donation but also reignited my entrepreneurial drive. I was driven by my desire to honor the generosity of tissue donors and address the persistent lack of human-derived biomaterials in the market, that’s why Humabiologics was founded. I leveraged the discard tissue to introduce the market’s first human collagen and gelatin bioinks.

Who inspired you the most along this journey?

Mohammad: I was fortunate enough to be trained, mentored, and inspired by several great individuals, each contributing in unique ways to my personal and professional growth. It all started with my Ph.D. advisor, Dr. Howard Matthew, who not only introduced me to the intricate world of cells and biomaterials but also instilled in me the confidence to transition from an engineer to a scientist. The trust of Drs. Anthony Atala and James Yoo to lead the skin bioprinting research group fueled my passion for leveraging technology to make a tangible difference in the lives of patients. In the clinical realm, Dr. James Holmes played a pivotal role in amplifying my dedication to regenerative medicine. Witnessing firsthand the transformative impact of innovative treatments on the quality of patients’ lives under his guidance further fueled my commitment to advancing the field. Transitioning to the industry sphere, I was fortunate to receive mentorship from Dr. Steve Charlebois during my tenure at COOK Medical. He enormously influenced my thinking and approach to tackling complex challenges in product development. I was then mentored by Ken Russel, whose entrepreneurial expertise and success in founding and selling a medical device company made me believe that one day I too could venture into entrepreneurship and make a meaningful impact in the healthcare industry.

What motivates you the most for your work? 

Mohammad: What motivates me most in my work is the profound sense of purpose and impact it carries. Every day, I am driven by the opportunity to honor the selfless act of tissue donation and to transform discarded tissue into valuable resources that have the potential to improve and even save lives. This connection to the donor’s wish is a constant reminder of the responsibility and privilege entrusted to me. Knowing that my efforts contribute to the development of unique products that empower scientists and clinicians to enhance the quality of human therapies further fuels my motivation. Being part of a process that drives innovation and facilitates advancements in regenerative medicine is incredibly fulfilling. Ultimately, the dual motivation of honoring the donor’s legacy and advancing the frontier of scientific discovery propels me forward, ensuring that each day is filled with purpose and meaning in my work.

What is/are the biggest obstacle(s) in your line of work? If you have conquered them, what were your solutions? 

Mohammad: The biggest obstacle was around the heavy reliance on animal-derived biomaterials in regenerative medicine research. These biomaterials not only pose ethical and regulatory challenges but also lack the clinical and physiological relevance necessary for effective translation into human therapies. Overcoming this hurdle required addressing several interconnected issues, including accessibility, affordability, and scalability of human-derived biomaterials. I recognized this critical need and set out to provide viable solutions. The primary focus was to develop a diverse portfolio of human-derived biomaterials that offer superior clinical relevance compared to animal-derived counterparts. By harnessing discarded human tissues, we pioneered the production of a wide range of biomaterials and prioritized accessibility, quality, and affordability to ensure widespread adoption within the research community. The FDA Modernization Act 2.0 which authorizes the use of certain alternatives to animal testing, such as bioprinted organoids, to investigate the safety and effectiveness of a drug has helped with the adoption of incorporating human biomaterials more and relying less on products derived from animal tissues. We also invested significant efforts in raising awareness and educating researchers about the clinical relevance of human-derived biomaterials, thereby overcoming skepticism and driving adoption. As a result of these initiatives, Humabiologics has successfully introduced 59 products to the market, serving over 100 customers in 23 countries across 5 continents. 

What do you think is (are) the biggest challenge(s) in bio-printing? What do you think the potential solution(s) is (are)?

Mohammad: There is no doubt that bioprinting has contributed to several advances in the field. The biggest challenge in bioprinting lies in the complexity of creating functional and viable constructs that can accurately mimic native tissues and organs. This involves addressing several key factors, including development of suitable multiculture systems, the precise incorporation of different cell types, optimization of cell concentrations, and selection of appropriate biomaterials among many other challenges. One potential solution to these challenges lies in advancing our understanding of tissue engineering principles and refining the techniques used in bioprinting. This includes further research into cell biology, biomaterial science, and tissue biomechanics to better replicate the intricate microenvironment of native tissues. Additionally, the development of advanced bioprinting technologies, such as multi-material printing and organ-on-a-chip systems, holds promise for enhancing the complexity and functionality of bioprinted constructs. By fostering partnerships and sharing knowledge across diverse fields, we can collectively overcome the challenges associated with bioprinting.

If you are granted three wishes by a higher being, what would they be? 

Mohammad: My first wish would be to eradicate cancer, sparing millions from its devastating impact and alleviating the suffering of patients and their loved ones. My second wish would be a world of safety and peace, where conflicts are resolved through dialogue and understanding, and where every individual can live without fear of violence or oppression. My last wish would be a healthy Earth, where ecosystems thrive, biodiversity flourishes, and the planet’s resources are cherished and sustainably managed for future generations. 

What advice would you give to a smart driven college student in the “real world”? What bad advices you heard should they ignore? 

Mohammad: Leave this life as a better place than when you came. Shoot for the moon but keep your feet on the ground. Stay humble and realistic. Never seek perfection because it can be paralyzing and counterproductive. Instead, focus on progress, growth, and continuous improvement. Never compare yourself or journey to others because everyone’s path is unique, and success is subjective. Never forget to prioritize your personal Well-being as it is the core of everything you do in life.  

What’s your favorite book you read this year and why? Alternatively, what’s your favorite book of all times you read and why?

Mohammad: While podcasts certainly are prevailing due to convenience in this time and era, there’s something special about a good book’s depth and immersive experience. I still like to read books that are more related to honing some essential business skills and fostering my personal development.

“Influencer” by Joseph Grenny and others, along with “Crucial Conversations: Tools for Talking When Stakes are High“. The books offer invaluable insights into navigating challenging conversations and influencing change effectively. In today’s dynamic and interconnected world, mastering these skills is essential for personal and professional growth. 

“Meetings Suck” by Cameron Herold sounds like a refreshing take on a common pain point in the business world. Efficient and productive meetings are crucial for driving collaboration and innovation, making this book a valuable resource for entrepreneurs and business leaders striving to optimize their team’s performance.

Lastly, “Coping with Difficult People” by Dr. Robert Bramson is a timeless classic that continues to resonate with readers across generations. The ability to effectively manage difficult personalities and navigate interpersonal challenges is indispensable in both professional and personal settings. This book provides practical strategies and insights for building constructive relationships and resolving conflicts with grace and tact.

Related Links:

Interview with Dr. Rao Bezwada: Absorbable Polymers for 3D Printing

Biomaterials Bioinks for 3D Printing(On Demand)

Interview with Dr. Wilson Wong: Novus Life Sciences

Interview with Dr. Bryan Scheer: From Bedside To SiNAPTIC Technologies

Interview with Julien Barthes: Silicone 3D Printing

The post Interview with Dr. Mohammad Albanna: Humabiologics appeared first on 3DHeals.

Last Thursday’s event focusing on 3D-printed orthopedic implants was eye-opening. By design, the event intends to provide education and organic discussion by international influencers with 3D printing, biomaterials, and regulatory and clinical expertise. The outcome of such talks based on the 3DHEALS virtual event format is often unpredictable, insightful, and inspirational at the same time. This event was no exception. Here are my quick after-thoughts on what I have learned and a few video clips. However, please don’t take my word for it. If you are a serious 3D-printed medical device maker or entrepreneur, you should bookmark this event and use it as a future reference. 

Speed is the Game.

Dr. Bryan Scheer, orthopedic surgeon, serial entrepreneur, CEO, and co-founder of SiNAPTIC Technologies, said the quicker the patient can get treatment/repair and heal, the better the clinical outcomes. That means the speed at which the device is ready for implantation, even if not custom-made. This also means the post-processing and design of 3D-printed devices must take “speed” into consideration.  The value of a patient-specific implant is still up in the air because the clinical outcomes for some of the PSI are not clearly superior yet. That said, for complex and especially revisional orthopedic cases, Dr. Harry Hothi demonstrated a clear example that 3D-printed personalized devices have a clear advantage. 

Why 3D printing?

Jennifer Palinchik, President and Co-Founder of JALEX Medical, LLC, who regularly consults for 3D-printed titanium implant device companies, clarifies why some device makers should consider 3D printing in one simple slide.  With these advantages of new technology, however, there are trade-offs, including a new regulatory pathway that can be complex and expensive to navigate. That said however, Jennifer mapped out steps to take a new 3d printed implant from idea to implementation.

Will bioceramics eat the world? 

Our event sponsor, Himed, who established the new Bioceramics Center of Excellence for 3D-printed ceramic implants, believes so.

Bryan Scheer’s new startup (SiNAPTIC) also focuses on a form of bioceramics: silicon nitrite. While most current orthopedic implants are made of metal/titanium, bioceramic implants have many advantages. These include high cell adhesion, enhanced osteoconductivity, superior bacterial resistance, reduced bacterial adhesion, and radio-opaque for imaging follow-ups. If you want to learn more about silicone nitride, here is a reference you can read more about.  SiNAPTIC Technology is currently working on foot and ankle implants made with silicon nitrite. 

Does 3D-printed porosity (and defects) matter? 

The answer is nuanced. 

Dr. Hothi, who has published extensively in the space with his collaborators at Royal National Orthopaedic Hospital (RNOH) NHS Trust, shared some of the results from his work on 3D-printed hip implants. While there is no conclusion on which type of lattice design will produce better osteointegration, many speakers chimed in that both 3D printing and lattice design serve many other benefits beyond just osteointegration. I am personally motivated to read all of Dr. Hothi’s publications in the near future. 

The rise of “metamaterial”? 

In the forward-looking part of the discussion, speakers discussed future “smart” biomaterials, implant design with cellular components or functionalities, and sensor-embedded implants. While Jennifer Palinchik knew the regulatory pathway would be particularly challenging, this idea energized the panel and is likely to be a focus of future innovations in the implant space. 

Related Links:

3D Bioprinting Biofabrication for Musculoskeletal Tissues (On Demand, 2024)

Best Practices in Central Europe: 3D Printed Maxillofacial Implants (On Demand, 2023)
Event Recap: 3D Bioprinting Biofabricating Skin Components
Event Recap: Point of Care 3D Printing
Event Recap: 3D Printing and AI in Orthopedics
Event Recap: Innovation in Melt-Electrowriting (MEW) & 3D Printing

Event Recap: In Silico Simulation for Medtech and Biopharma

The post Quick Take: 3D Printed Orthopedic Implants appeared first on 3DHeals.

Point of care 3D printing (POC 3DP) offers an exciting opportunity to fabricate patient-specific medical devices and models within the clinical setting.  Such models can help explain procedures to patients and for surgical planning, while custom-made implants can improve patient care.  At our recent 3DHEALS event, we learned about the latest from five experts bringing the future of POC 3DP to life.

Benefits of point-of-care 3D printing

Dr. Mark Tan, Radiologist and Clinical Lead of the Singapore General Hospital 3D Printing Centre, recognizes POC 3DP’s potential to improve treatment efficacy, increase efficiency, expand options for physicians, and increase a hospital’s resiliency during shortages.

Dr. Tan described that POC 3DP can be a crucial component in treating trauma cases where time is limited.  The convenience of having a readily accessible 3DP lab within the hospital enables fast turnaround times for printing patient-specific devices and delivering them to surgeons.

Dr. Tan also pointed out that POC can be particularly useful in cases where there is not a high market demand for the hospital’s desired 3D-printed object. Having the capability for a hospital to print itself can help meet that need when outsourcing cannot. Additionally, the proximity of a lab makes it easier for surgeons to provide input while making highly complex surgical guides and other intricate prints.

Starting POC 3DP at a hospital

Shannon Walters, Executive Technical Director of Stanford University’s 3D and Quantitative Imaging Laboratory, shared some important prerequisites for starting POC 3DP.

One starting point for individuals looking to build POC 3DP is acquiring the necessary space for 3D printers, as not all rooms within a clinical facility may be suitable for 3DP.  Factors such as adequate ventilation for user safety, proper printer power sources, and the potential for allergic reactions to certain printing materials should be considered.  Walters said they could not do powder bed printing after considering allergic reactions.

Another critical component is establishing rapport with the hospital’s specialties by identifying pain points and showing that 3DP can provide value to them.  As Dr. Tan mentioned, physicians requiring fast delivery times or frequent input during the process may find value in POC 3DP.  Determining how to track the POC 3DP program’s efforts early on becomes valuable for providing evidence to funding sources and securing space.

Walters noted the importance of iterating on and optimizing workflows. Individuals setting up POC 3DP can coach physicians on reducing the number of materials asked for in a print and help them determine whether printing at full scale can be avoided. Other methods include finding better ways to remove support material and identifying better segmentation software.

Another piece of the puzzle is managing 3D printing orders.  Chris LeCastillo, Innovations Manager of the Stanford 3D and Quantitative Imaging Laboratory, talked about how they started by taking requests using email and tracking orders using Smartsheet, a third-party management platform.  While their foray into POC 3DP had a humble beginning with one FDM printer, LeCastillo showed how their lab successfully scaled up.

Now, the 4-printer, 11-member team receives requests through the medical records system Epic and tracks prints using in-house software.  The lab continues to grow by expanding its ordering process to its children’s hospital and building upon its quality management system.

POC 3DP in action: use cases

Dr. Neha Sharma, Deputy Head of the Medical Additive Manufacturing (Swiss MAM) Research Group and the 3D Print Lab at University Hospital Basel, is using POC 3DP to enhance craniomaxillofacial surgeries.  Dr. Sharma and colleagues designed an MDR-complaint workflow for 3D printing patient-specific polyetheretherketone (PEEK) cranial implants.

Dr. Sharma described how they used POC 3DP to fabricate a cranial implant for a patient, starting with in-house imaging and design of the implant.  They were able to print the device within 4-5 hours, sterilize within the same day, and have it implanted the next day.

Bringing 3D printing into clinical institutions also has the benefit of training residents and healthcare providers who need to become knowledgeable in the increasing use of 3D printing in the medical field.  Dr. Sharma presented their outreach activities and courses, including their involvement in the upcoming September Symposium on 3D Printing for Life Sciences in Basel.

Making POC 3DP attainable

An essential step towards advancing POC 3DP is to lower the barrier for hospitals to start innovating in this area.  Brian Overshiner, Manager of the Ricoh 3D for Healthcare Innovation Studio, explained to us how the company has created an end-to-end workflow to make POC 3DP more attainable for hospitals.

With a press of a button, physicians can directly send patient scans from their hospital’s radiology viewer to Ricoh and work with their biomedical engineers to segment the images.  This focus on creating end-to-end platforms streamlines the handling of the various logistics involved in POC 3DP, such as Ricoh’s feature of incorporating a quality control management system into this process.

Recently, the company announced their POC 3DP manufacturing facility with Atrium Health Wake Forest Baptist to produce patient-specific anatomical models.

Outlook for POC 3DP

While POC 3DP presents substantial benefits, several challenges remain.  For example, Walters noted that it is optional for healthcare insurance to cover 3D printing as part of a patient’s care.  Such coverage, however, does not pay for other essential components such as technologists, materials, and printers.  Dr. Sharma also talked about how reimbursements are still not covered in Europe even if hospital management sees the value in 3D printing.  Managing these costs will be necessary for POC 3DP programs in the future.

Building the necessary quality management system and taking steps to ensure regulatory compliance for POC 3DP will also be critical for hospitals moving forward.

While POC 3DP has its fair share of logistical challenges, the opportunity to bring the customizability of 3DP to the clinic will propel patient care further with improved implants and increased use of patient-specific anatomical models.  Sharing and commercializing solutions to these logistical hurdles, such as print management software and quality control systems, can be an effective path forward.  To join our future events live and stay updated with the latest in this area, subscribe to 3DHEALS.

About the Author:

Peter Hsu

Peter Hsu is an editorial intern for 3DHEALS.  He is currently an undergraduate at the University of Illinois Urbana-Champaign and studies bioengineering with a focus on cell and tissue engineering.  He is also minoring in computer science with interests in artificial intelligence and image processing.  Peter conducts research on using computer vision methods to analyze human tissue images and improving the robustness of machine learning workflows.  He is interested in the use of AI to assist tissue engineering and bioprinting research for medical applications.  He is passionate about science communication and leads STEM outreach lessons at schools in the central Illinois area.

Relevant Links:

Event Recap: 3D Printing and AI in Orthopedics
Event Recap: Innovation in Melt-Electrowriting (MEW) & 3D Printing

Event Recap: In Silico Simulation for Medtech and Biopharma

3D Printing At the Point of Care (On Demand, 2024)

Dental 3D Printing 2024: What’s New (On-Demand, 2024)

The post Event Recap: Point of Care 3D Printing appeared first on 3DHeals.

A virtual patient.  That’s what we’re looking for to reduce costs and accelerate the innovation of medical devices and treatments, including those using 3D printing.  And it is these virtual patients that can be a crucial component in helping entrepreneurs and researchers bolster their products for clinical trials. We sat down with five experts who are making computer, or in silico, simulations a reality to benefit patients worldwide.  Here’s a recap of the progress they’ve made and the challenges to come from our 3DHEALS event.

The conventional pathway for developing a medical device can be fraught with expense if problems are found too late in the process.  In silico simulations provide an avenue for researchers and companies to discover effective solutions faster and detect issues earlier.

Already, the United States Food and Drug Administration (FDA) has recognized the increasing utility of computational modeling and recently established guidance on assessing the credibility of in silico evidence for medical device submissions.

Virtual Patients, Not Too Far Away

Simon Sonntag, CEO and Co-Founder of Virtonomy, is streamlining the use of these types of computer simulations using virtual patient cohorts, or simulated versions of patients that mimic a variety of anatomical conditions with the goal of maximal population coverage.  This could be a potentially cost-effective way to test 3D-printed devices before clinical trials and provide evidence for the trials themselves.

Sonntag described how testing a device for transcatheter applications, such as replacing a heart valve, can be challenging due to the variability in vessel tortuosity and diameters between patients.  Virtonomy’s database of computed tomography scans enables them to model a diverse range of vascular geometries for the transfemoral, inferior vena cava, subclavian/jugular vein, and transseptal via the fossa ovalis access routes.

For vessel straightening, the company can simulate the device materials, catheterization process, arterial material, surrounding organs and bones, and calcification. 3D models like these allow users to readily tune anatomical features with their software, testing worse-case scenarios and inclusion-exclusion criteria that can then be used as evidence for regulatory assessments.

Within only a 3-week submission window for a severely ill patient, the company was able to perform in silico fatigue simulations, which provided critical evidence to the German regulatory agency that approved the implantation of the heart valve repair system.

In Silico Simulation Can Help 3D Printed Implants

Companies are also developing software for other parts of the body.  Kelsey Crossman, Business Development Manager for Simq, describes how the company’s software performs biomechanical simulations of maxillary and mandibular patient-specific implants.  Their product, Simq VIT, automates device validation by simulating physiological load conditions and generates FDA-compliant reports as valuable objective evidence of the design process.  The implant can then be 3D printed with greater confidence in point-of-care applications or sent to a manufacturer.

Crossman says their software simulates various chewing conditions, allowing engineers and clinicians to revise their designs based on deformation data before they print.  The company has also developed simulations for virtual patient cohorts and is expanding to thoracic applications.

In Silico Simulation Compliments 3D Printing in Complex Surgical Cases

Also using simulation techniques, Dr. Péter Éltes, Head of the In Silico Biomechanics Laboratory at the National Center for Spinal Disorders in Hungary, recognizes that simply designing custom implants that fit the natural geometry after the surgical removal of structures is not enough.

Dr. Éltes’ recent study uses finite element analysis to determine the stability of lumbopelvic reconstruction after removal of the sacral bone due to a tumor.  Through their in silico analysis, they find that reducing the lumbopelvic distance is needed to increase stability.  Future custom-made 3D-printed implants can now be designed with this added stability technique in mind, showing the potential of computer simulations to inform the engineering of commercial and research 3D-printed medical devices for better clinical outcomes.

Regulatory Landscape Promising but Remains Promising

We have already seen that in silico simulations hold promise in accelerating clinical trials.  Building justification for that potential, Steven Kreuzer, Senior Managing Engineer at Exponent Inc., co-led a team involving the FDA and Dassault Systèmes to retrospectively examine the benefits in silico simulation would have had for an approved mitral transcatheter edge-to-edge repair device to reduce heart valve regurgitation.

Kreuzer describes how they created a tunable virtual patient model for various heart valve anatomies, accounting for differences in thickness, stiffness, and other properties between different valve leaflets.  They then created virtual patient cohorts with a wide distribution of valve properties, looking at the grade reduction in regurgitation among the patients to evaluate the acute device performance.

In Silico Simulation for Pharma Developers, A Different Beast

In silico simulation has applications in drug discovery and development, in addition to medical devices.  Anthony Fejes, CEO and Co-Founder of HTuO Biosciences, is preparing to commercialize the company’s software, which performs physics-based simulations to predict drug behavior. Their software bridges the gap between the high accuracy of quantum mechanics-based simulations and the scalability of molecular modeling software.

In external validation, Fejes showed that the company’s product AtomForge could reduce errors in modeling molecule torsion angles by 82% and out-of-plane errors by 84% for the worst-case scenario, a significant improvement compared to a prior state-of-the-art, the generalized AMBER force field, on the nonsteroidal anti-inflammatory drug mefenamic acid.  The company has also shown lower errors for other drugs that are difficult to simulate compared to OpenFF, another state-of-the-art method.

Perhaps one day, we could combine such drug simulation platforms with 3D bioprinted tissues for in vitro studies of drug candidates, potentially accelerating the process further compared to traditional animal testing.

While in silico simulations have been shown to be a promising avenue for a larger number of use cases, various challenges remain.  For example, Kreuzer notes that work still needs to be done to garner wider acceptance of these technologies for clinical trials.

Sonntag also points out that there could be hurdles if there are differences in the kinds of in silico clinical trial data certain countries will accept, emphasizing the importance of harmonizing regulatory standards internationally.

Additionally, certain artificial intelligence-based simulations may require large amounts of training data, limiting their applicability.

Our speakers show that computational simulations have immense potential to continue growing in their number of use cases, and the 3D printing industry will benefit from the acceleration of the device development and clinical trial process.  To listen in on the full discussion with our speakers, you can watch the recording of our event, and subscribe to join our upcoming events live.

Peter Hsu

Peter Hsu is an editorial intern for 3DHEALS.  He is currently an undergraduate at the University of Illinois Urbana-Champaign and studies bioengineering with a focus on cell and tissue engineering.  He is also minoring in computer science with interests in artificial intelligence and image processing.  Peter conducts research on using computer vision methods to analyze human tissue images and improving the robustness of machine learning workflows.  He is interested in the use of AI to assist tissue engineering and bioprinting research for medical applications.  He is passionate about science communication and leads STEM outreach lessons at schools in the central Illinois area.

Related Links:

Event Recap: Innovation in Melt-Electrowriting (MEW) & 3D Printing

In Silico Simulation for Medtech and Biopharma (Full Recording, On Demand, 2024)

Interview with Zsolt Pásztor: In Silico Simulation and 3D Printing

Interview with Simon Sonntag: CEO, Virtonomy

Virtual Reality Software For Molecular Modeling and Structure-Based Drug Design

3D Printing for Medical Simulation (On Demand)

Design for Medical 3D Printing (On Demand)

Point of Care 3D Printing (On Demand)

Interview with Kelsey Crossman: Simq Simulation

The post Event Recap: In Silico Simulation for Medtech and Biopharma appeared first on 3DHeals.

3D technologies for treating spinal diseases, especially degenerative diseases, are becoming a sub-universe within the orthopedic sphere. In this event, we will invite experts working on the research and commercialization of spinal devices, from software to hardware to service providers, to discuss how big and deep 3D printing is in this industry.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Craig Johnson

Craig is a Boston native, where he grew up and went to school with a degree in Mechanical Engineering. After years of working in product design and manufacturing, he quickly fell in love with the magic of 3D printing, focusing on helping grow innovation of all types. Soon, he was introduced to the medical side of 3D printing, immediately saw the impact, and wanted to focus on helping the amazing people expanding that industry. Now, as one of Materialise’s Account Managers, he focuses on medical device development and the use of Mimics software solutions to use digital anatomy to improve results. Coming from additive manufacturing, he strives to teardown inefficiencies and is here to help bring time savings and automation to medical device workflows.

Ruben Wauthle

Ruben started his career at LayerWise (now 3D Systems) in 2010 as a Medical Application Engineer and obtained a PhD in Mechanical Engineering in 2014 from KU Leuven on the topic of 3D printing porous titanium and tantalum implants. Between 2015 and 2020, he held various management positions in additive manufacturing contract manufacturing and equipment sales. Since 2020, Ruben is co-founder and CEO of Amnovis. Amnovis is a manufacturing and engineering company that uses innovative 3D printing technologies and materials for high-end applications such as titanium spinal implants. They are an ISO 13485 certified and FDA registered contract manufacturer, providing a smooth pathway to help customers achieve FDA clearance for their 3D printed medical devices.

Erez Lampert

I am an Electrical Engineer (M.sc,, MBA) with a track record of almost 20 years in leading multi-disciplinary team in developing innovative products in various fields. In 2018, together with leading spine surgeons, I founded PathKeeper Surgical. Our goal is to make spine surgery better by creating a safer, radiation free and affordable spine surgery navigation solution. Since Feb 2012, I have led the R&D HW team responsible for new scanner development in Align technologies. In addition, I am part on the management team of Align technologies of the Israeli office in 2013, we launched the new iTero, The best intra-oral scanner in the world. Before joining Align technologies, I held various R&D leadership positions in both start-ups and large corporations, leading large groups of engineers in both direct and matrix structure, always looking for transformational innovation.

Ian Helmar

Ian Helmar, founder of NanoHive Medical, developed the proprietary lattice which is the basis for NanoHive’s product portfolio. Ian has over 10 years of engineering experience in the spine market, designing complex instruments and 3D printed spinal implants. Since 2016, Ian has served as head of Research and Development and has led the development of all of NanoHive’s product lines. Ian holds a B.S. in Mechanical Engineering from Rensselaer Polytechnic Institute.

Moderators:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Matthew Henshaw

Matthew Henshaw has worked as a headhunter for over a decade. A strong business background and thousands of hours on the phone to professionals, from multiple countries, has equipped him with an unique outlook on commercialising MedTech innovation. This means his clients enjoy relevant industry insight and advice, as well as being introduced to candidates that have a powerful impact on the growth of their business.

Sponsor:

The post 3D Technologies & 3D Printing for the Spine 🗓 appeared first on 3DHeals.

MELT electrowriting printing technology is a cutting-edge method that enables the precise fabrication of intricate structures at the micro- and nanoscale levels. This technology involves the controlled deposition of molten polymer fibers using electric fields, allowing for the creation of customized structures with high resolution and accuracy. In healthcare, MELT electrowriting has significant potential for various applications. For instance, it can be used to produce scaffolds for tissue engineering, where the precise arrangement of fibers can mimic the native tissue architecture and support cell growth and differentiation. Additionally, this technology can aid in developing drug delivery systems by creating microscale capsules or fibers capable of controlled release of therapeutic agents. Furthermore, MELT electrowriting has been explored to fabricate biosensors and diagnostic devices, offering a versatile and adaptable platform for advancing healthcare technologies.
Join a panel of leading experts to explore the challenges and future of MEW printing and how it can reshape the landscape of medtech innovation.  

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Naomi Paxton

Dr. Naomi Paxton is a Senior Research Fellow in the field of biofabrication & 3D printing, and leader of the Bioinspired Additive Manufacturing (BioAM) group. With a background in physics, Naomi was part of the inaugural cohort for the dual international Biofabrication Masters degree and has completed her research training in world-leading international labs in Australia, Germany, the UK and USA. In 2020, Naomi completed her PhD in partnership with Melbourne-based medical device company, Anatomics, through the ARC Industrial Transformation Training Centre in Additive Biomanufacturing. Dr. Paxton’s research involves combining advanced biomaterials to 3D print scaffolds that replicate natural biological systems and promote regeneration. For example, Naomi’s research uses a range of biomaterials and composites to fabricate patient-specific surgical implants and focuses on the use of melt electrowriting (MEW), an advanced additive manufacturing technique which allows the deposition of micron-scale fibres in ordered 3D constructs.

Paul Dalton

Paul Dalton is an Associate Professor at the University of Oregon who specializes in manufacturing technologies for biofabrication. He is credited with inventing and developing melt electrowriting, a distinct class within 3D printing. His research on medical implants involves the use of high-resolution 3D printing and simultaneously promotes grassroots open-source hardware development and low-cost approaches in biomedical engineering. With over 25 years of hands-on experience, his expertise spans various fields, including biomaterials, nanotechnology, tissue engineering, neuroimmunology, experimental surgery, biofabrication, and 3D printing. His interdisciplinary and international perspective is reflected in his previous research and residences in Australia, Canada, China, the UK, and Germany before relocating to the US.

Bahram Mirani

Bahram Mirani is a Ph.D. candidate at the University of Toronto, working on tissue engineering of heart valves. Combining melt electrowriting with computational modelling and design of experiments, he has developed a method to recapitulate the complex nonlinear, anisotropic mechanical behaviour of native soft connective tissues such as valve tissue – essential for their function, regulation, and homeostasis – in tissue-engineered constructs. Before his Ph.D., Bahram obtained his Master’s degree in mechanical engineering from the University of Victoria, Canada, where he focused on tissue engineering, wound healing, and drug delivery.

Filippos Tourlomousis

Filippos is the founder & CEO of Biological Lattice Industries Corp., a VC-backed startup that is developing an AI-driven robotic biofabrication platform for tissue engineering and regenerative medicine applications. In addition to that, Filippos is the Chief Scientist of “Superlabs, The Laboratory for Autonomous Science” at NCSR Demokritos funded by the EU Resilience and Recovery Fund (Greece 2.0). His main research interests lie in the field of intelligence for the automation of science and robotics infrastructure for self-driving materials engineering labs of the future (a.k.a. “robot scientists”).

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Now on Demand:

Subscribe here to receive event emails.

The post Melt-Electrowriting And/Or 3D Printing 🗓 appeared first on 3DHeals.

What is the next frontier of medical device and biotech innovation?  Don’t miss this upcoming virtual event, “3D Microfabrication 2.0.” Joined by leading experts and pioneers in the field, this event promises to unveil the transformative potential of 3D microfabrication techniques in revolutionizing the landscape of medical device manufacturing. From intricate implants to specialized instruments, participants will gain exclusive insights into how micro or nano-scale 3D printing is reshaping the design, production, and functionality of medical devices with unprecedented precision and efficiency at a micro-scale using a variety of biomaterials. Could bio-chips (microfluidics devices), robotic and endoscopic tips, and microneedles be the next frontier of international technological competition like that for the semiconductor industry? Join the conversation live and find out!

Note: If you can’t make it on time, you can register and watch the conversation on-demand for a week after the live event ends.

Live event participation is FREE to all public.

Starting Time: 8:00 AM Pacific Time

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Dr. Benjamin Richter

Benjamin Richter is an Application Manager at Nanoscribe and develops microfabrication processes and applications for the life sciences. Before, he completed an interdisciplinary PhD thesis on “Selective Biofunctionalization of 3D Microstructures” in the groups of Prof. Wegener, Prof. Bastmeyer and Prof. Barner-Kowollik at KIT. His scientific papers have been cited more than 1500 times (Google Scholar).

Chunguang Xia

CTO and co-founder of Boston Micro Fabrication (BMF). Chunguan was trained as a mechanical engineer and worked in the semiconductor equipment industry for eight years before starting BMF Precision. Recently, BMF Biotechnology Inc. developed biochips for in vitro drug testing.

Jungho Choi

Jungho is a Ph.D candidate at Gatech with a background in mechanical engineering. His research is specialized in micro/nanoscale manufacturing. I aim to develop a new metal/polymer additive manufacturing system and generate the processing science for a rapid and cost-effective nanoscale fabrication system.

Talk title, “Scalable printing of metal nanostructures through superluminescent light projection”

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Now on Demand:

Subscribe here to receive event emails.

The post 3D Microfabrication 2.0 🗓 appeared first on 3DHeals.